CA3209477A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
CA3209477A1
CA3209477A1 CA3209477A CA3209477A CA3209477A1 CA 3209477 A1 CA3209477 A1 CA 3209477A1 CA 3209477 A CA3209477 A CA 3209477A CA 3209477 A CA3209477 A CA 3209477A CA 3209477 A1 CA3209477 A1 CA 3209477A1
Authority
CA
Canada
Prior art keywords
cancer
methylenediamine
pharmaceutically acceptable
subject
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3209477A
Other languages
English (en)
French (fr)
Inventor
Yanping Kong
Jinhong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3209477A1 publication Critical patent/CA3209477A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3209477A 2021-02-02 2022-01-28 Compositions and methods for treating cancer Pending CA3209477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144690P 2021-02-02 2021-02-02
US63/144,690 2021-02-02
PCT/US2022/014379 WO2022169690A1 (en) 2021-02-02 2022-01-28 Composition and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA3209477A1 true CA3209477A1 (en) 2022-08-11

Family

ID=82742455

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3209477A Pending CA3209477A1 (en) 2021-02-02 2022-01-28 Compositions and methods for treating cancer

Country Status (8)

Country Link
US (1) US20240099992A1 (https=)
EP (1) EP4288040A4 (https=)
JP (1) JP2024506999A (https=)
KR (1) KR20230142733A (https=)
CN (1) CN117083061A (https=)
AU (1) AU2022218110A1 (https=)
CA (1) CA3209477A1 (https=)
WO (1) WO2022169690A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560522A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
JPWO2011002026A1 (ja) * 2009-06-30 2012-12-13 国立大学法人 熊本大学 アミロイド線維形成抑制剤及びその利用
RU2417999C2 (ru) * 2009-07-13 2011-05-10 Закрытое Акционерное Общество "Ива Фарм" БИЯДЕРНЫЕ КООРДИНАЦИОННЫЕ СОЕДИНЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ d-ЭЛЕМЕНТОВ С АЛИФАТИЧЕСКИМИ ТИОЛАМИ КАК СРЕДСТВА ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
JP2011084541A (ja) * 2009-10-19 2011-04-28 Ltt Bio-Pharma Co Ltd 低分子薬物含有ナノ粒子
CA3064486C (en) 2017-04-20 2023-08-01 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound

Also Published As

Publication number Publication date
KR20230142733A (ko) 2023-10-11
AU2022218110A1 (en) 2023-08-17
US20240099992A1 (en) 2024-03-28
CN117083061A (zh) 2023-11-17
JP2024506999A (ja) 2024-02-15
EP4288040A1 (en) 2023-12-13
EP4288040A4 (en) 2025-01-08
WO2022169690A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
US10266505B2 (en) Compositions and methods for treating cancers
CA2508536A1 (en) An exopolysaccharides delivery system for active molecules
Indap et al. Quercetin: Antitumor activity and pharmacological manipulations for increased therapeutic gains.
WO2019217164A1 (en) Compositions and methods for treating cancer and other diseases
NL8301913A (nl) Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren.
EP4424316A1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
US20250275938A1 (en) Compositions and methods for treatment of cancer
US20240099992A1 (en) Compositions and methods for treating cancer
JP6234553B2 (ja) 抗癌剤および副作用軽減剤
JP7186731B2 (ja) 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
KR20180117681A (ko) 글리코알칼로이드 조합 및 그의 다양한 용도
US20180055915A1 (en) Compositions and methods for treating prostate cancer
EP3782620B1 (en) Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
HK40103289A (zh) 用於治疗癌症的组合物和方法
CN115634228B (zh) 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用
WO2017079003A1 (en) Deuterated compounds for treating blood cancers, and compositions and methods thereof
RU2471486C2 (ru) Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное
FR2910813A1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2016073733A1 (en) Methods of treating cancer using lipopeptides
CN121177494A (zh) Ipi549和bmn673联合在治疗白血病中的应用
RU2452485C1 (ru) Соли 1,3-диэтилбензимидазолия - средства для лечения онкологических заболеваний и фармацевтические композиции на их основе
HK40025641B (zh) Mcl-1抑制剂与用於血液癌症的标准治疗的组合，其用途和药物组合物
KR20140105231A (ko) 펜톡시필린을 포함하는 항암치료 보조제

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260105

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106